Lambisia Arnold W, Murunga Nickson, Mutunga Martin, Cheruiyot Robinson, Maina Grace, Makori Timothy O, Nokes D James, Agoti Charles N
Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), P.O. Box 230, Kilifi, 80108, Kenya.
School of Life Sciences and Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, Coventry, CV4 7AL, UK.
Gut Pathog. 2024 Jan 4;16(1):2. doi: 10.1186/s13099-023-00595-4.
The non-pharmaceutical interventions (NPIs) implemented to curb the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) early in the coronavirus disease 2019 (COVID-19) pandemic, substantially disrupted the activity of other respiratory viruses. However, there is limited data from low-and-middle income countries (LMICs) to determine whether these NPIs also impacted the transmission of common enteric viruses. Here, we investigated the changes in the positivity rate of five enteric viruses among hospitalised children who presented with diarrhoea to a referral hospital in coastal Kenya, during COVID-19 pandemic period.
A total of 870 stool samples from children under 13 years of age admitted to Kilifi County Hospital between January 2019, and December 2022 were screened for rotavirus group A (RVA), norovirus genogroup II (GII), astrovirus, sapovirus, and adenovirus type F40/41 using real-time reverse-transcription polymerase chain reaction. The proportions positive across the four years were compared using the chi-squared test statistic.
One or more of the five virus targets were detected in 282 (32.4%) cases. A reduction in the positivity rate of RVA cases was observed from 2019 (12.1%, 95% confidence interval (CI) 8.7-16.2%) to 2020 (1.7%, 95% CI 0.2-6.0%; p < 0.001). However, in the 2022, RVA positivity rate rebounded to 23.5% (95% CI 18.2%-29.4%). For norovirus GII, the positivity rate fluctuated over the four years with its highest positivity rate observed in 2020 (16.2%; 95% C.I, 10.0-24.1%). No astrovirus cases were detected in 2020 and 2021, but the positivity rate in 2022 was similar to that in 2019 (3.1% (95% CI 1.5%-5.7%) vs. 3.3% (95% CI 1.4-6.5%)). A higher case fatality rate was observed in 2021 (9.0%) compared to the 2019 (3.2%), 2020 (6.8%) and 2022 (2.1%) (p < 0.001).
Our study finds that in 2020 the transmission of common enteric viruses, especially RVA and astrovirus, in Kilifi Kenya may have been disrupted due to the COVID-19 NPIs. After 2020, local enteric virus transmission patterns appeared to return to pre-pandemic levels coinciding with the removal of most of the government COVID-19 NPIs.
在2019冠状病毒病(COVID-19)大流行早期实施的非药物干预措施(NPIs),极大地扰乱了其他呼吸道病毒的活动。然而,来自低收入和中等收入国家(LMICs)的数据有限,无法确定这些NPIs是否也影响了常见肠道病毒的传播。在此,我们调查了在COVID-19大流行期间,肯尼亚沿海一家转诊医院中出现腹泻的住院儿童中五种肠道病毒阳性率的变化。
对2019年1月至2022年12月期间入住基利菲县医院的13岁以下儿童的870份粪便样本,使用实时逆转录聚合酶链反应筛查A组轮状病毒(RVA)、II型诺如病毒基因组(GII)、星状病毒、萨波病毒和F40/41型腺病毒。使用卡方检验统计量比较这四年中阳性的比例。
在282例(32.4%)病例中检测到五种病毒靶点中的一种或多种。观察到RVA病例的阳性率从2019年的12.1%(95%置信区间(CI)8.7 - 16.2%)降至2020年的1.7%(95% CI 0.2 - 6.0%;p < 0.001)。然而,在2022年,RVA阳性率回升至23.5%(95% CI 18.2% - 29.4%)。对于诺如病毒GII,阳性率在这四年中波动,2020年观察到其最高阳性率(16.2%;95% C.I,10.0 - 24.1%)。2020年和2021年未检测到星状病毒病例,但2022年的阳性率与2019年相似(3.1%(95% CI 1.5% - 5.7%)对3.3%(95% CI 1.4 - 6.5%))。与2019年(3.2%)、2020年(6.8%)和2022年(2.1%)相比,2021年观察到更高的病死率(9.0%)(p < 0.001)。
我们的研究发现,2020年在肯尼亚基利菲,常见肠道病毒,尤其是RVA和星状病毒传播可能因COVID-19 NPIs而受到干扰。2020年之后,当地肠道病毒传播模式似乎恢复到疫情前水平,这与政府大部分COVID-19 NPIs的解除相吻合。